Prognostic impact of molecular markers in a series of 220 primary glioblastomas. - Wikidata - awgldk - TriplyDB

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

http://www.wikidata.org/entity/Q48602532

about

Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients Epidemiologic and molecular prognostic review of glioblastoma The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway.Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.Clinical and molecular models of glioblastoma multiforme survival 1p/19q testing has no significance in the workup of glioblastomas.Long-Term Survival of a Patient with Giant Cell Glioblastoma: Case Report and Review of the Literature Haplotype analysis of the 5,10-methylenetetrahydrofolate reductase (MTHFR) c.1298A>C (E429A) polymorphism Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study.Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.How molecular testing can help (and hurt) in the workup of gliomas.Canadian recommendations for the treatment of glioblastoma multiforme.Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.Applications of emerging molecular technologies in glioblastoma multiforme Molecularly targeted therapies for malignant gliomas.Gliomatosis cerebri: growing evidence for diffuse gliomas with wide invasion.Biomarkers of clinical responsiveness in brain tumor patients : progress and potential.EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.Epigenetic markers in human gliomas: prospects for therapeutic intervention.Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.Transcriptome analysis of glioma cells for the dynamic response to γ-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas.Prognostic markers of astrocytoma: how to predict the unpredictable?Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century.Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.Using the molecular classification of glioblastoma to inform personalized treatment.Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.Aptamer-conjugated nanoparticles for cancer cell detection.Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients.Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.Interleukin-6 gene amplification and shortened survival in glioblastoma patients.Something old and something new about molecular diagnostics in gliomas.

P2860

Q27022941-5DF6F02D-C362-4A2C-A2CD-25D3FEEA9777 Q28300822-93A9C44D-F907-4360-9787-DD5D501CE934 Q28395302-C5E1449B-09D9-408D-9D41-1F5D84B9A9AA Q30442283-CB33D396-58D1-4216-B782-BF9E8A0678F8 Q31016728-252F9223-FCDA-4175-AE24-9A7A3A054213 Q33601633-BEFC8D47-D419-43D2-B53F-21AE430C96CE Q33893445-47413A16-BC51-43FA-8848-0161CFE4D541 Q34054790-3031F131-6C00-43D4-A59D-6E44DD1C3DEE Q34056679-DCD17DC5-08D1-4528-98AC-F99BA4B7EBFF Q34132650-2D4AF437-2288-4940-A06A-35E2BF593DA1 Q34149065-C4F54E13-3BB6-4F7D-917E-6F33746E7C58 Q34430791-73DE01E5-CF46-4111-8153-CB097A61632D Q34583151-A778A9B3-2923-4289-B8F7-26656FCB7360 Q34769934-D20DA8A3-2FBD-4A41-9AF1-01FDB51FF0B4 Q35356484-08CDD249-1A44-4FC9-873F-C185526BF422 Q35770275-CC08D479-DB40-4557-A08E-E1C69BB38A3E Q35855352-411370D9-49C0-4FB5-A340-97A145A8E5D9 Q35862636-926A42C0-7D40-487A-B583-A03DD1CFBE91 Q36087220-98E9AB11-A758-4660-ADB3-238A3B52C7E5 Q36965370-8A320CFE-8FEA-4584-AE23-4918ADC7F8B1 Q37107374-0FDD4A79-4ABF-4224-A3D0-66CEBFE80DEF Q37139776-E1C0CADF-4B35-40FA-A610-1124A6403A3A Q37225840-E87B9A3D-CFA3-4DE5-923F-A5922932E30C Q37284242-A3F45814-39B5-46EE-95A6-269E964014D2 Q37301207-8C69673D-025A-44E2-848D-494BF3D72FD3 Q37312716-087CFE2A-8A14-456E-AF05-80BE39CB37BA Q37577423-A2874FC7-3F9E-4CCD-89CA-4CE9835CF0EB Q38089921-BD8331CF-EDF9-4507-8B98-AE991E9113C4 Q38101368-EA00FF97-4A2A-4071-BF4A-9EB726EB182C Q38112074-7BEB7F5D-F98E-424F-9ACD-2862D65FB765 Q38151582-770EB887-7829-413C-8D6E-91CC24419009 Q38601004-D68BB4F3-37AD-419C-B4F4-235DA01A2EED Q39036566-2F096853-0862-4506-97CC-3F3A84EFED61 Q39610225-C87A810D-0A02-4D8D-A8E7-289B453CAA5A Q40990401-1173877E-C21A-4F07-BBC3-3CAF00521DFC Q41110170-23D303B4-F872-4C5A-A9B1-EB2ABA1C5E43 Q41822859-8769E120-BB88-456D-87EB-A104258FAF9D Q41842448-654DA4E0-8956-4D26-93C0-F38F71965E8B Q42549981-5ADABF96-71BF-4BDD-862D-4852A7D61CB5 Q43238974-D7E940EC-DA35-4E34-9620-C3F5A6E2FDE7

P2860

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

http://www.wikidata.org/entity/Q48602532

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@en

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@nl

type

label

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@en

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@nl

prefLabel

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@en

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@nl

P1433

Q48602532-18E83760-E057-4602-B021-48E8E1C9C789

P1476

Q48602532-30ED4350-22EF-4913-B6A2-3468A8F1A888

P2093

Q48602532-4D58F24E-28D1-46CE-9C3F-6824676DB67B

Q48602532-54045925-CC89-4BC6-8057-4CCC4103062D

Q48602532-855FEEA1-53C2-4F41-98FC-189234DCB6E3

Q48602532-BAB3C5D1-782F-4D9D-A3A9-A2A5A6D392AC

Q48602532-C40E9474-F6FC-48BB-8779-4431BECCBAAE

Q48602532-CDF6913E-6C3B-4E96-AFD4-8B22BB2B113B

Q48602532-CF0743CC-789C-4CC7-B22B-5ED948DDFF7F

Q48602532-E6AC2A37-8D12-42D0-88DA-73233DF2056B

Q48602532-F32121C3-EDE8-4D73-9A78-C5827B4EDCE3

P2860

Q48602532-88EF7701-B543-4E89-8CB4-52571E0986F6

Q48602532-8AE79EA5-4BD7-49FA-A243-A96B21E9C79E

Q48602532-D030254A-B53E-441D-A668-DC64074DDBF8

P304

Q48602532-EEF0E340-8499-4E45-B18E-A349198BE586

P31

Q48602532-E04F1DD1-D7CB-43E9-9E2B-8ED7C2450C06

P356

Q48602532-67E898A8-C632-4149-BA59-E9C8E40B513F

P407

Q48602532-C4BB83F2-2173-4BA2-A0BE-0EABC62664EC

P433

Q48602532-F57E9DDA-DD45-416E-B26E-3C0EF346C248

P478

Q48602532-869F48B3-0A4C-4BC4-8558-5D70C38E8C8A

P50

Q48602532-54E2BE49-3DFB-44A1-8FDD-9DB3656BAE52

P577

Q48602532-2782109B-CF7A-4242-A5A1-C2CC31D46699

P5875

Q48602532-6FE6BEA0-6C68-465B-80DD-BB513999CFC9

P698

Q48602532-81263AFE-0569-4ADA-B22D-DBCD0D5BDC48

P356

P1433

P1476

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

@en

P2093

Caroline Houillier

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Criniere

http://www.w3.org/2001/XMLSchema#string

Florence Laigle-Donadey

http://www.w3.org/2001/XMLSchema#string

Jean-Yves Delattre

http://www.w3.org/2001/XMLSchema#string

Joelle Thillet

http://www.w3.org/2001/XMLSchema#string

Julie Lejeune

http://www.w3.org/2001/XMLSchema#string

Karima Mokhtari

http://www.w3.org/2001/XMLSchema#string

Khe Hoang-Xuan

http://www.w3.org/2001/XMLSchema#string

Marc Sanson

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of genotype and morphology on the prognosis of glioblastoma.

Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.

Glioblastomas with an oligodendroglial component: a pathological and molecular study.

P304

2218-2223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.21819

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Alexandra Benouaich-Amiel

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227606175

http://www.w3.org/2001/XMLSchema#string

P698

16568472

http://www.w3.org/2001/XMLSchema#string